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Flash-lamp pulsed-dye laser (FPDL) is a nonablative technology, typically used in vascular malformation therapy due to its
specificity for hemoglobin. FPDL treatments were performed in a large group of patients with persistent and/or recalcitrant different
dermatological lesions with cutaneous microvessel involvement. In particular, 149 patients (73 males and 76 females) were treated.
They were affected by the following dermatological disorders: angiokeratoma circumscriptum, genital and extragenital viral warts,
striae rubrae, basal cell carcinoma, Kaposi’s sarcoma, angiolymphoid hyperplasia, and Jessner-Kanof disease. They all underwent
various laser sessions. 89 patients (59.7%) achieved excellent clearance, 32 patients (21.4%) achieved good-moderate clearance, 19
patients (12.7%) obtained slight clearance, and 9 subjects (6.1%) had low or no removal of their lesion. In all cases, FPDL was
found to be a safe and effective treatment for the abovementioned dermatological lesions in which skin microvessels play a role in
pathogenesis or development. Further and single-indication studies, however, are required to assess a standardized and reproducible
method for applying this technology to “off-label” indications.
1. Introduction
Flash-lamp pulsed-dye laser (FPDL) is a nonablative laser
technology that has gained an excellent reputation in the
treatment of vascular lesions. It uses a rhodamine dye that is
dissolved in a solvent and pumped by a flash-lamp producing
an emission of a 595 nm wavelength, approximately near
to the hemoglobin’s and oxyhemoglobin’s absorption peaks.
It is therefore considered the most specific laser currently
available for the treatment of superficial vascular lesions.
Current indications of this technology have further been
extended to include nonvascular lesions but with vascular
structural involvement, whichmakes themamenable to being
treated with such laser.
FPDL does not always represent the first-line treatment
for all these lesions: in fact, many lesions can be success-
fully treated using different treatment methods, and others
(viral warts and molluscum contagiosum) may sometimes
disappear without external intervention; therefore, the spec-
ification of when FPDL could be beneficial is crucial. Der-
matological lesions that represent the target may be con-
sidered typical vascular lesions, vascular dependent lesions,
or nonvascular lesions, according to a recent classification
[1].
Vascular lesions include not only port-wine stains, super-
ficial hemangiomas, and telangiectasias in which dye laser
is considered the gold standard therapy but also angioker-
atomas and lesions typical of the Bourneville-Pringle syn-
drome that may be treated surgically or through cryotherapy.
Vascular dependent lesions can be divided into the
following: viral infections such as verruca vulgaris and genital
viral warts, inflammatory skin diseases such as example local-
ized psoriasis and lupus erythematosus, connective tissue
diseases such as hypertrophic scars, keloids, and striae rubrae,
neoplastic dermatosis such as basal cell carcinoma, Kaposi’s
sarcoma and, angiolymphoid hyperplasia.
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Figure 1: Type of lesions.
Nonvascular lesions, on the other hand, include viral
infections like molluscum contagiosum as well as other cuta-
neous conditions, for example, xanthelasma palpebrarum
[1–13].
We selected a number of vascular dependent lesions and
nonvascular lesions in an open study in order to verify the
outcome of FPDL treatments.
2. Materials and Methods
A total of 149 patients affected by angiokeratoma circum-
scriptum (5), Jessner-Kanof disease (4), genital and extra-
genital viral warts (54), striae rubrae (10), angiolymphoid
hyperplasia (3), basal cell carcinoma (70), and Kaposi’s
sarcoma (3) were selected for treatment. Figure 1.
Patients underwent different treatment sessions with the
FPDL (Synchro Vas-Q, Deka MELA, Florence, Italy) as
indicated by Table 1.
All patients underwent treatment after obtaining a
detailed personal history (skin type, clinical manifestations,
health conditions, previous medications, and life-style) and
informed consent.
Five cases of angiokeratoma circumscriptum with pres-
ence of asymptomatic warty, keratotic nodules localized on
the external genitals of adult men were treated using a
10600 nm CO
2
laser (Smartxide2 Dot/RF, DEKA MELA,
Florence), at 0.2–0.5W, 10Hz in order to obtain vaporization
prior to three FPDL sessions.
Four patients with histological diagnosis of Jessner-Kanof
disease, a benign yet chronic lymphocytic skin disorder, were
treated in four FPDL laser sessions (Figure 2).
Fifty-four patients affected from viral warts (30 males
and 24 females), between the ages of 6 and 75 years (mean
34.39 years old), were recruited with a total of 85 warts. The
(a)
(b)
Figure 2: (a) A patient affected by Jessner-Kanof disease at baseline.
(b) The disappearance of the lesions 12 months after the last PDL
session.
majority were children (range 6–18 years old) with localiza-
tion on the hands (20 patients); in particular, lesions were
located on the hands (palms, dorsum, and the fingertips), the
periungual and subungual region, on the feet (12 patients)
especially on the soles, in one case, on the fifth finger, and on
the face (2 patients). Twelve of the older patients presented
lesions on the periungual and subungual regions and eight
of them had genital warts. All warts underwent at least
one prior established treatment without success. All patients
in the study were treated with the flash-lamp pumped-dye
laser (three to seven treatment sessions every four weeks),
preceded by curettage of the typical hyperkeratosis through
salicylic acid 30% ointment, especially for the mosaic plantar
warts (Figure 3).
Ten patients with striae rubrae were also treated with
the FPDL. Four to six sessions of FPDL were employed in
the treatment of striae which had the following localiza-
tions: abdomen/groin (3 patients), axilla/anterior shoulder (4
patients), and buttock/upper thigh (3 patients).
Three young females affected by angiolymphoid hyper-
plasia whose diagnosis was based on clinical and histological
findings were selected in the present study. Patients received
a previous radiotherapy with no results. In all these cases,
patients were treated in three sessions using FPDL in addition
to ablative CO
2
laser (0.5–0.7W) in order to obtain complete
vaporization of the lesions.
Seventy patients (38 males and 32 females, aged 47 to
78) with superficial and nodular nonpigmented basal cell
carcinoma (BCC), diagnosed after dermoscopic evaluation,
were recruited. Most parts of the lesions were characterized
by limited size (diameter < 1 cm) (Figure 4). The basal cell
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Table 1: Specific PDL approaches for the different cutaneous disorders.
Type of lesions Patients Sessions of PDL Parameters Combination with CO2 laser
Angiokeratoma circumscriptum 5 3
Wavelength 595 nm
Energy 6-7 J/cm2
Spot size 12mm
Pulse 0.5–1.5ms
X
Jessner-Kanof disease 4 4
Wavelength 595 nm
Energy 6-7 J/cm2
Spot size 12mm
Pulse 0.5–1.5ms
Viral warts 54 3–7
Wavelength 595 nm
Energy 6-7 J/cm2
Spot size 12mm
Pulse 0.5–1.5ms
Striae 10 4–6
Wavelength 595 nm
Energy 6-7 J/cm2
Spot size 12mm
Pulse 0.5–1.5ms
Angiolymphoid hyperplasia 3 3
Wavelength 595 nm
Energy 6-7 J/cm2
Spot size 12mm
Pulse 0.5–1.5ms
X
Superficial and nodular basal cell
carcinoma (BCC) 70 5
Wavelength 595 nm
Energy 6-7 J/cm2
Spot size 12mm
Pulse 0.5–1.5ms
Kaposi’s sarcoma 3 4
Wavelength 595 nm
Energy 6-7 J/cm2
Spot size 12mm
Pulse 0.5–1.5 ms
(a) (b) (c)
Figure 3: (a) A viral wart of the finger at baseline. (b) The typical immediate purpura after the PDL therapeutical session. (c) The excellent
result achieved after 5 PDL treatments.
carcinomas were localized mainly on the face and neck
area and in anatomically difficult areas as the nasal wings
or the periocular zone. One patient had an allergy to
anesthetics and five were cardiopathic, which limited the
usage of surgical excision. All patients were subject to FPDL
in five sessions with a 595 nm wavelength that enabled
deeper penetration to the target (oxyhemoglobin or nuclear
chromatin).
Three patients with classic Kaposi’s sarcoma were treated
with four FPDL sessions. The reason for treatments was
due to the inability to undergo surgery or poor response to
pharmacological treatments.
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Figure 4: (a) A superficial basal cell carcinoma from the back of a woman at baseline. (b) The typical purpura due to PDL. (c) The
disappearance of the lesion 12 months after the last PDL session.
Table 2: Global improvements.
Score 1 Score 2 Score 3 Score 4
Low or no removal of their lesion Slight clearance Moderate-good clearance Excellent clearance
9 (6%) 15 (10%) 23 (15.4) 102 (68.4%)
Table 3: Subjective evaluations show that the vast majority of subjects were satisfied or very satisfied.
Unsatisfied Not very satisfied Satisfied Very satisfied
2 (1.3%) 14 (9.3%) 23 (15.4%) 110 (73.8%)
A summary of the methodology used for the different
indications is provided in Table 1.
Laser fluence settings for all diseases were 6–8 J/cm2, a
spot size of 12mm, and a pulse duration of 0.5–1.5ms.
Most of the lesionswere treatedwithout anesthesia. Its use
has been limited as the procedure itself was not so painful
and also because local anesthesia could cause oedema and
hinder the “visual feedback processing” during treatment. An
effective cooling device was always used during each laser
session, improving comfort. Patients were instructed to avoid
sun and cosmetics during the immediate postprocedural
periods and to apply cool gauzes, emollient creams, and
sunscreens until complete recovery. Daily application of cool
wraps was useful to prevent the appearance of vesicles and
blisters. An antibiotic ointment, gentamicin 0.1%, was also
requested to be applied to the target areas for 7 days after each
laser session, avoiding potential cutaneous superinfections.
3. Results
Results obtained were judged immediately and 4 weeks after
the last session; treatment outcome was assessed by ranking
the results into four categories, a quartile scale, of lesion
clearance in comparison to baseline: 1 indicates no or low
results (0–25% of the lesion area cleared), 2 indicates slight
clearance (25–50% of the lesion area cleared), 3 indicates
moderate-good clearance (50–75%), and 4 indicates excellent
clearance (75%–100%).
Patients were asked for a subjective evaluation of the
perceived overall results by means of the following score:
unsatisfied, not very satisfied, satisfied, and very satisfied.
All patients observed global improvements (Figures 2–5
(a), (b), and (c)). All the lesions were completely removed
except in the case of 7 patients with striae rubrae where
lesions did not disappear at 12-month follow-up and two
cases of BCCwhich showed a recurrence that was completely
excised through surgery four weeks later.
102 patients (68.4%) achieved excellent clearance, 23
patients (15.4%) achieved good-moderate clearance, 15
patients (10%) obtained slight clearance, and 9 subjects (6%)
had low or no removal of their lesion (Table 2).
Patients were asked for a subjective evaluation of the
results: 110 patients (73.8%) were very satisfied, 23 (15.4%)
were satisfied, and 14 (9.3%) were not very satisfied with
the results, whereas only 2 patients (1.3%) were unsatisfied
(Table 3); the low satisfaction rate was due probably to long-
term purpura produced by the use of higher parameters
which caused discomfort; dissatisfaction with the results was
due to higher expectations in case of 2 patients with striae.
Relevant side effects, such as blisters, crusts, atrophy,
and scars, were absent in all conditions; many patients
showed typical FPDL-induced side effects like swelling and
BioMed Research International 5
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Figure 5: (a) Kaposi’s sarcoma of the penis, baseline. (b) A temporary little ulcer after 3 PDL sessions. (c) The final result 12 months after the
last PDL session, with no side effects and a great satisfaction of the patient.
Total lesions clearance
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Figure 6: Results.
purpura, which disappeared three to ten days after treatment.
Five patients reported long-lasting purpura (30 days). See
Figure 6.
4. Discussion and Conclusion
Although intense flash-lamp pulsed-dye laser (FPDL) is
normally used in vascular malformation therapy, we treated
patients with a number of nonvascular indications.
The study evidences an overall patient improvement that
may represent a valid alternative to other procedures.
A correct selection of patients using FPDL is the most
useful strategy, as this technique is beneficial in selected
patients, such as those with persistent and/or recalcitrant
dermatological disorders with vessel involvement. Pediatric
population, for example, may become alarmed by treatment
and refuse painful procedures resulting in poor patient
compliance [14]. Cardiopathic patients, subjects using anti-
coagulant drugs or unable to receive anesthesia, have great
difficulty in undergoing surgical treatment and are thereby
more likely to be candidates for FPDL treatment. Lastly,
surgical devices are not recommended in certain areas, such
as the face, neck, nose, nasal wings, groins, and anogenital
areas, due to the risk of disfiguring scars or keloids.
We believe that the success of FPDL treatment lies in
the fact that most of the lesions mentioned contain a large
number of dilated blood vessels which represent the target of
the device.Themechanismof action of FPDL is thereby based
on specific destruction of abnormal vessels, components of
the lesions themselves (angiokeratoma circumscriptum and
striae rubrae), or a selective thrombosis of vessels with the
consequent obliteration of the nutrient supply to the lesions
(viral wart, angiolymphoid hyperplasia, Kaposi’s sarcoma,
and basal cell carcinoma).
Also, authors recently demonstrated that the 585 nm
FPDL can decrease fibroblast proliferation and collagen type
III deposition and furthermore may induce apoptosis and
upregulation of extracellular signal-regulated kinase and p38
mitogen-activated protein kinase activity. Its use may be
therefore extended to other dermatological conditions such
as keloids [15–18].
In this study, similar to previous studies [19], different
vascular or vascular dependent lesions were treated using
FPDL laser alone or in combination with pulsed CO
2
laser.
FPDL in all cases was reported to be a safe, well-tolerated,
and effective treatment method and may be considered an
alternative or a complementary treatment for resistant and/or
recalcitrant lesions or when contraindications do not suggest
the use of other therapies.
Its use, however, should be limited to selected cases in
which labelled therapies have not proved effectiveness or
when patients are unable to undergo such treatments. Also,
off-label proceduresmust always be carried out carefully, with
a strict follow-up in order to ensure safety.
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The high cost of the proceduremay represent a limit in its
use, despite the excellent aesthetic outcome of results.
Future multicentrical studies on single indications, how-
ever, are desirable, with possible harmonization of the meth-
ods and parameters used.
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